JJ and SJ performed experiments. activation in a Ascomycin (FK520) similar manner as IVIG. Moreover, bIgG was able to mediate T cell activation and internalization of pathogens, which are prerequisites for inducing an adaptive viral response. Using mouse experiments, we showed that bIgG is able to bind the murine activating IgG Fc Receptors (FcR), but not the inhibiting FcRII. Intranasal administration of the monoclonal antibody palivizumab, but also of bIgG and IVIG prevented RSV infection in mice. The concentration of bIgG needed to prevent infection was ~5-fold higher compared to IVIG. In conclusion, the data presented here indicate that functionally active bIgG facilitates adaptive antiviral T cell responses and prevents RSV infection and were opsonized with 500 ug/ml IVIG or bIgG or without antibody in 100 l 1% bovine serum albumin (BSA)-RPMI1640 for 15 min on ice. Washed bacteria were incubated in an effector: target ratio of 1 1:100 with 1 10e5 bone marrow derived WT mouse macrophages in V bottom 96 well plates (Greiner) for 30 min on ice. Cells were washed Ascomycin (FK520) with 100 ul ice-cold 1% BSA medium and equally divided over 2 wells prior to addition of opsonized bacteria. One part was incubated at 37C for internalization, while the other part was stained directly. Extracellular immune complexes (IC) were stained with 200x diluted Alexa647 conjugated hIgG (Jackson) or bIgG (Jackson) on ice. A decrease in extracellular signal is considered as internalized IC. In addition, cells were washed, fixated with 1% PFA and analyzed by flow cytometry (BD Bioscience, Canto II and FACS Diva software). RSV Prophylactic Mouse Model Female FcRC/C C57BL/6 mice or wild-type female littermates of the same age were used. Mice were anesthetized (3C4% isoflurane) and administered intranasal with 50 l antibody diluted in PBS with a varying dosing (0.2C5 mg/kg) of bIgG or IVIG or with a fixed dose of 5 mg/kg bIgG or 1 mg/kg for a similar prophylactic effect on the viral load. Palivizumab was used at 0.05 mg/kg. Mice were intranasally infected with 3 10e6 PFU RSV-A2-RL-Line19F in 50 l PBS after 24 h. Mice were euthanized by intraperitoneal injection of sodium pentobarbital 5 days post infection. A bronchioalveolar lavage was performed, after inflating the lungs, with 1 ml PBS and used to determine the viral load, as described previously (24). Statistical Analysis Statistical analysis was performed using GraphPad Prism 6 software. An unpaired Student’s < 0.05, **< 0.01, ***< 0.001, ****< Ascomycin (FK520) 0.0001. All graphs represent mean SD of triplicate measurements, unless indicated otherwise. Results Bovine IgG Binding and Neutralization of RSV For this study we made use of RSV-A2 and the more pathogenic strain RSV-A2-RL-Line19F, to evaluate whether the binding of purified bovine colostrum IgG (bIgG) and purified human plasma IgG (IVIG) is equal between both strains. HEp-2 cells were infected with RSV and dose-dependent binding of bIgG and IVIG was analyzed. Binding was compared to the clinically used antibody palivizumab (human IgG1 against RSV F protein). bIgG bound to the RSV-A2 infected cells, as shown previously, starting Mouse monoclonal to MER from a concentration of 1 1.2 g/ml bIgG. Binding of bIgG was equal to cells infected with both RSV strains, similar to what was observed with IVIG and palivizumab (Figure 1A). Open in a separate window Figure 1 bIgG RSV binding and neutralization. Antibody binding of serial diluted palivizumab (Pali),.
Recent Posts
- The complete sequence of hepatitis E virus genotype 4 reveals an alternative strategy for translation of open reading frames 2 and 3
- different from control *Significantly; not the same as control and from 1 and 14 days **significantly; not the same as pretarsal control #significantly
- We thank W
- The significance from the differences in immune responses for these viruses, furthermore to any differences in the consequences of molecular mimicry can’t be dependant on our study
- Methods Virol
Recent Comments
Archives
- February 2025
- January 2025
- December 2024
- November 2024
- October 2024
- September 2024
- May 2023
- April 2023
- March 2023
- February 2023
- January 2023
- December 2022
- November 2022
- October 2022
- September 2022
- August 2022
- July 2022
- June 2022
- May 2022
- April 2022
- March 2022
- February 2022
- January 2022
- December 2021
- November 2021
- October 2021
- September 2021
- August 2021
- July 2021
Categories
- Orexin Receptors
- Orexin, Non-Selective
- Orexin1 Receptors
- ORL1 Receptors
- Ornithine Decarboxylase
- Orphan 7-TM Receptors
- Orphan 7-Transmembrane Receptors
- Orphan G-Protein-Coupled Receptors
- Orphan GPCRs
- OT Receptors
- Other Acetylcholine
- Other Adenosine
- Other Apoptosis
- Other ATPases
- Other Calcium Channels
- Other Cannabinoids
- Other Channel Modulators
- Other Dehydrogenases
- Other Hydrolases
- Other Ion Pumps/Transporters
- Other Kinases
- Other MAPK
- Other Nitric Oxide
- Other Nuclear Receptors
- Other Oxygenases/Oxidases
- Other Peptide Receptors
- Other Pharmacology
- Other Product Types
- Other Proteases
- Other RTKs
- Other Synthases/Synthetases
- Other Tachykinin
- Other Transcription Factors
- Other Transferases
- Other Wnt Signaling
- OX1 Receptors
- OXE Receptors
- Oxidative Phosphorylation
- Oxoeicosanoid receptors
- Oxygenases/Oxidases
- Oxytocin Receptors
- P-Glycoprotein
- P-Selectin
- P-Type ATPase
- P-Type Calcium Channels
- p14ARF
- p160ROCK
- P2X Receptors
- P2Y Receptors
- p38 MAPK
- p53
- p56lck
- p60c-src
- p70 S6K
- p75
- p90 Ribosomal S6 Kinase
- PAC1 Receptors
- PACAP Receptors
- PAF Receptors
- PAO
- PAR Receptors
- Parathyroid Hormone Receptors
- PARP
- PC-PLC
- PDE
- PDGFR
- PDK1
- PDPK1
- Peptide Receptor, Other
- Peptide Receptors
- Peroxisome-Proliferating Receptors
- PGF
- PGI2
- Phosphatases
- Phosphodiesterases
- Phosphoinositide 3-Kinase
- Phosphoinositide-Specific Phospholipase C
- Phospholipase A
- Phospholipase C
- Phospholipases
- Phosphorylases
- Photolysis
- PI 3-Kinase
- PI 3-Kinase/Akt Signaling
- PI-PLC
- PI3K
- Pim Kinase
- Pim-1
- PIP2
- Pituitary Adenylate Cyclase Activating Peptide Receptors
- PKA
- PKB
- PKC
- PKD
- PKG
- PKM
- PKMTs
- PLA
- Plasmin
- Platelet Derived Growth Factor Receptors
- Platelet-Activating Factor (PAF) Receptors
- Uncategorized